SEC Form 4 · STOCK Act

Insider buys that paid off for the people who copied them.

$ZSTK

ZeroStack Corp.

+206.0%

Michael Heinrich, Executive Chair, bought $3.5M. Filed Jul 20, 6:31 PM ET.

COPIED JUL 21

$1,000 copied at the first price after the filing (Jul 21 open, $1.66) was $3,060 30 trading days later.

Example. Of 339 buys of $100K or more filed Jun 29 to Sep 11, the median lost 5.3% and 67.8% lost money over the same 30 trading days. Not investment advice.

Officers and directors must report their own stock purchases within two business days. We list every one, largest first, with what copying it would have returned.

A free account keeps a watchlist. No password: we email you a link.

RUBYBuy

Rubius Therapeutics, Inc.

David R Epstein · Director

$43K+1.0%Apr 22
RUBYSell

Rubius Therapeutics, Inc.

Pablo J Cagnoni · CEO and President

$44K−16.0%Feb 1
RUBYBuy

Rubius Therapeutics, Inc.

Flagship Ventures Fund IV General Partner LLC · 10% owner

$6.1M+1.0%Mar 23
RUBYSell

Rubius Therapeutics, Inc.

Maiken Keson-Brookes · CLO, Corp. Secretary

$506K−100.0%Mar 15
RUBYSell

Rubius Therapeutics, Inc.

David R Epstein · Director

$399K−1.0%Feb 16
RUBYSell

Rubius Therapeutics, Inc.

David R Epstein · Director

$1.5M−2.0%Feb 10
RUBYBuy

Rubius Therapeutics, Inc.

David R Epstein · Director

$39KMar 17
RUBYSell

Rubius Therapeutics, Inc.

Christopher L. Carpenter · Chief Medical Officer

$647K−58.0%Dec 18
RUBYSell

Rubius Therapeutics, Inc.

Robert Langer · Director

$64K−100.0%Oct 17
RUBYSell

Rubius Therapeutics, Inc.

Christopher L. Carpenter · Chief Medical Officer

$485K−58.0%Sep 18
RUBYSell

Rubius Therapeutics, Inc.

Robert Langer · Director

$112K−100.0%Jul 17
RUBYSell

Rubius Therapeutics, Inc.

Christopher L. Carpenter · Chief Medical Officer

$670K−58.0%Jun 19
RUBYSell

Rubius Therapeutics, Inc.

Robert Langer · Director

$132K−100.0%Apr 17
RUBYSell

Rubius Therapeutics, Inc.

Torben Straight Nissen · President

$42KApr 10
RUBYSell

Rubius Therapeutics, Inc.

Torben Straight Nissen · President

$252K−1.0%Apr 5
RUBYSell

Rubius Therapeutics, Inc.

Christopher L. Carpenter · Chief Medical Officer

$760K−58.0%Mar 19
RUBYSell

Rubius Therapeutics, Inc.

Robert Langer · Director

$109K−100.0%Jan 18
RUBYBuy

Rubius Therapeutics, Inc.

Catherine A. Sohn · Director

$58KJul 23
RUBYBuy

Rubius Therapeutics, Inc.

Francis M Cuss · Director

$230KJul 23
RUBYBuy

Rubius Therapeutics, Inc.

Jonathan Symonds · Director

$575KJul 23

Filings come from SEC EDGAR within a minute of the SEC accepting them. Without Pro, each one unlocks 4 hours later. Not investment advice.

Questions

Where does the data come from?

Corporate insider trades come straight from SEC Form 4 filings, pulled from EDGAR within a minute of each filing. Congress trades come from STOCK Act disclosures. All of it is public and free to browse here, and Pro sees the newest filings first.

How often is it updated?

Every minute from 6 AM to 10 PM New York time on weekdays, the hours the SEC accepts filings. Pro sees each filing as it lands. Without Pro, a filing unlocks 4 hours after the SEC accepts it.

Is following insider trades legal?

Yes. Insiders are legally required to disclose their trades within a few days. Acting on those public disclosures is completely legal. Trading on private, non-public information is illegal, but that's a different thing.

What does the iPhone app add?

We're building an iPhone app that alerts you to new filings and, if you choose, copies a buy into your own brokerage after you approve it. It isn't out yet, and the waitlist is free.